Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73341
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73341
Character Range: 14677–15631

73341              Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of locally advanced or metastatic non‑small cell lung cancer, which is of non‑squamous histology or histology not otherwise specified, with documented evidence of anaplastic lymphoma kinase (ALK) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score > 0, and with documented absence of activating mutations of the epidermal growth factor receptor (EGFR) gene, requested by a specialist or consultant physician, if the test is:                                                                        400.00
                     (a) to determine if requirements relating to ALK gene rearrangement status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled; and
                     (b) not associated with a service to which item 73437 or 73439 applies